Inhibrx Biosciences, Inc.
Research score, not a recommendation.
Market data
Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.
–
Why this score
Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.
Why are they buying?
No explanation has been generated for this cluster. The filings in the table below are the primary evidence.
Stock Price & Insider Purchase History
Daily close price with open-market insider purchases plotted over time
Loading price history…
| Date | Insider | Role | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2024-08-20 → 2024-09-16 | Lappe Mark 4 purchases with a 63-day result · median -15.5% | CEO | 164,000 | $14.73 avg | $2.4M | |
| 2024-08-20 | Lappe Mark | 27,055 | $12.97 | $350.9K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-08-21 | Lappe Mark | 12,945 | $12.93 | $167.4K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-08-29 | Lappe Mark | 10,000 | $14.03 | $140.3K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-08-30 | Lappe Mark | 10,000 | $14.02 | $140.2K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-03 | Lappe Mark | 4,712 | $16.31 | $76.9K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-03 | Lappe Mark | 15,288 | $15.66 | $239.4K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-06 | Lappe Mark | 26,000 | $15.29 | $397.5K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-09 | Lappe Mark | 9,500 | $15.21 | $144.5K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-10 | Lappe Mark | 8,500 | $15.19 | $129.1K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-12 | Lappe Mark | 26,963 | $15.05 | $405.8K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-09-16 | Lappe Mark | 13,037 | $17.13 | $223.3K | SEC filing for Lappe Mark (opens in a new tab) | |
| 2024-08-22 → 2024-08-23 | FORSYTH DOUGLAS history of FORSYTH DOUGLAS's purchases | Director | 75,000 | $13.83 avg | $1.0M | |
| 2024-08-22 | FORSYTH DOUGLAS | 15,188 | $12.89 | $195.8K | SEC filing for FORSYTH DOUGLAS (opens in a new tab) | |
| 2024-08-23 | FORSYTH DOUGLAS | 59,812 | $14.07 | $841.6K | SEC filing for FORSYTH DOUGLAS (opens in a new tab) | |
| 2024-08-29 → 2024-10-03 | Vuori Kristiina MD 3 purchases with a 63-day result · median -12.3% | Director | 20,443 | $14.67 avg | $300.0K | |
| 2024-08-29 | Vuori Kristiina MD | 7,140 | $14.00 | $100.0K | SEC filing for Vuori Kristiina MD (opens in a new tab) | |
| 2024-09-10 | Vuori Kristiina MD | 179 | $15.00 | $2.7K | SEC filing for Vuori Kristiina MD (opens in a new tab) | |
| 2024-09-11 | Vuori Kristiina MD | 6,457 | $15.07 | $97.3K | SEC filing for Vuori Kristiina MD (opens in a new tab) | |
| 2024-10-03 | Vuori Kristiina MD | 6,667 | $15.00 | $100.0K | SEC filing for Vuori Kristiina MD (opens in a new tab) | |
| 2024-08-28 | MANHARD KIMBERLY history of MANHARD KIMBERLY's purchases | Director | 10,000 | $13.98 | $139.8K | SEC filing for MANHARD KIMBERLY (opens in a new tab) |
| Total | $3.9M | |||||
Other buying runs at INBX
A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
After this run became a cluster: 21 days +5.0%63 days -8.3%126 days -3.8%
| Window | Insiders | Total | Score | 21 days | 63 days | 126 days | Status |
|---|---|---|---|---|---|---|---|
| 2026-09-08 → 2026-10-14 | 3 | $6.3M | 73 | -15.8% | – | – | active |